TrialPsychopharmacology2021

The novel vasopressin receptor (V1aR) antagonist SRX246 reduces anxiety in an experimental model in humans: a randomized proof-of-concept study.

Tiffany R Lago et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.